{"brief_title": "The Safety and Effectiveness of Megace in HIV-Infected Women", "brief_summary": "To further evaluate the safety of megestrol acetate (Megace) oral suspension in the treatment of anorexia and cachexia in HIV-positive women. To compare the effectiveness of 2 doses of Megace by measurement of weight gain, appetite grade, and other parameters at 12 and 24 weeks.", "detailed_description": "Patients are randomized to receive 1 of 2 doses of Megace oral suspension daily for 24 weeks; at 12 weeks, those receiving the lower dose who have not gained 5 pounds over baseline or had appetite improvement to good or excellent are escalated to the higher dose. Patients are evaluated at 4-week intervals. Dose may be adjusted to maintain a desired weight.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Megestrol acetate", "criteria": "Inclusion Criteria Patient must have: - HIV infection. - Evidence of HIV wasting syndrome that includes anorexia (appetite fair or poor) and weight loss >= 10 percent of pre-illness body weight. - Perception of weight loss as a detriment. - Life expectancy of at least 24 weeks. Prior Medication: Allowed: - Megestrol acetate for weight gain at a dose < 400 mg for < 60 days, provided therapy was discontinued at least 3 months prior to study entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Poorly controlled hypertension. - Heart failure. - Deep vein thrombosis. - Uncontrolled severe diarrhea. - Treatable active current infection (excluding chronic low-grade opportunistic infections). - Unable to intake food. - Impaired digestive/absorptive function. Concurrent Medication: Excluded: - Initiation during the study of any therapy to treat HIV or anorexia/cachexia (other than study drug). Patients with the following prior conditions are excluded: - Hospitalization for or exacerbation of illness associated with weight loss within the past 2 weeks. - Participation in other investigational drug studies within the past month. - Previous abnormal mammogram (if 35-40 years of age) or abnormal mammogram within the past year (if over 40 years of age). Prior Medication: Excluded: - New antiviral therapy within the past 8 weeks. - Medications to promote weight gain (e.g., corticosteroid, dronabinol) within the past 2 months. - Megestrol acetate within the past 3 months. IV drug abuse not treated for at least 4 months.", "gender": "Female", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002345.xml"}